EARNEST Partners’s Biostage, Inc. Common Stock BSTG Stock Holding History

EARNEST Partners’s Portfolio BSTG Stock Details BSTG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-650	Closed	-$1K	–	1115
2016 Q4	$1K	Hold	650	–	–	﹤0.01%	1128
2016 Q3	$1K	Hold	650	–	–	﹤0.01%	384
2016 Q2	$1K	Hold	650	–	–	﹤0.01%	387
2016 Q1	$1K	Hold	650	–	–	﹤0.01%	395
2015 Q4	$1K	Hold	650	–	–	﹤0.01%	389
2015 Q3	$1K	Hold	650	–	–	﹤0.01%	394
2015 Q2	$1K	Hold	650	–	–	﹤0.01%	389
2015 Q1	$2K	Hold	650	–	–	﹤0.01%	384
2014 Q4	$2K	Hold	650	–	–	﹤0.01%	394
2014 Q3	$5K	Buy	+650	New	+$5.32K	﹤0.01%	374

Other funds holding BSTG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

WIC

Woodmont Investment Counsel Nashville, Tennessee $1.83B AUM 25.91% 1-Year Est. Return

State of New Jersey Common Pension Fund D Trenton, New Jersey $29.3B AUM 38.15% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

EARNEST Partners's BSTG Position: Q1 2017 in Review

EARNEST Partners sold out of Biostage, Inc. Common Stock (BSTG) in Q1 2017, closing a stake of 650 shares — an estimated $1K sold.

EARNEST Partners first reported a position in BSTG in Q3 2014 and held it in 10 quarters. The position peaked at $5K in Q3 2014. 24 funds tracked by Wall St. Rank hold BSTG as of Q1 2017.

EARNEST Partners reported no remaining Biostage, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
EARNEST Partners sold 650 Biostage, Inc. Common Stock shares in Q1 2017, an estimated $1K.
EARNEST Partners first reported a position in Biostage, Inc. Common Stock in Q3 2014 and held it in 10 quarters.
EARNEST Partners's Biostage, Inc. Common Stock position peaked at $5K in Q3 2014.
24 funds tracked by Wall St. Rank held Biostage, Inc. Common Stock as of Q1 2017.

Based on EARNEST Partners's 13F filing for Q1 2017, filed 15 May 2017.